Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial
In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on cardiovascular events.
Source: medscape.com